论文部分内容阅读
CD4~+CD25~+Foxp3~+调节性T细胞可以有效抑制同种异体反应时细胞介导的免疫反应,近年来是器官移植领域学者关注热点之一。既往研究表明,Tregs既存在于移植器官受体的各级淋巴组织中,而且也分布在移植物内部中。因为Tregs的活化位置不同,其免疫抑制功能也不同,如果Tregs用来预防免疫排斥反应的话,那么Tregs在体定位和迁移信息特别关键。趋化因子受体是CD4~+CD25~+Foxp3~+Treg进行靶向迁移、在特定部位发挥免疫调节作用的结构基础。Tregs在体迁移是一个由多个细胞、多种趋化因子及其受体参与的运动过程。随着淋巴组织中新的趋化因子受体和Tregs特异性趋化因子的发现,提示Tregs在体复杂的迁移过程和活化主要是由趋化因子及受体介导。因此,趋化因子领域的研究将会为器官移植病人提供新的治疗思路。
CD4 ~ + CD25 ~ + Foxp3 ~ + regulatory T cells can effectively suppress cell-mediated immune response during allogeneic reaction, which is one of the hot topics in the field of organ transplantation in recent years. Previous studies have shown that Tregs exist both in lymphoid tissues at all levels of the transplanted organ and are also distributed within the graft. Because of the different activation sites of Tregs, their immunosuppressive functions are also different. If Tregs are used to prevent immune rejection, Tregs are particularly crucial for localization and migration of information. Chemokine receptor is CD4 ~ + CD25 ~ + Foxp3 ~ + Treg targeted migration, in the specific part of the immune regulatory role play a structural basis. Tregs in vivo Migration is a process of movement involving multiple cells, multiple chemokines and their receptors. With the discovery of new chemokine receptors and Tregs-specific chemokines in lymphoid tissues, it is suggested that the complex process of Tregs migration and activation is mainly mediated by chemokines and receptors. Therefore, research in the field of chemokines will provide new therapeutic options for organ transplant patients.